Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.60 |
| ▸ | CCR5 | P51681 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430797 | 1.00 | MAOB (0.60) | MAOBCCR5USP2LMNAMAOA | |
| SCHEMBL13886069 | 1.00 | MAOB (0.60) | MAOBCCR5USP2LMNAMAOA | |
| SCHEMBL14206846 | 0.92 | MAOB (0.65) | MAOBCCR5USP2LMNAMAOA | |
| SCHEMBL13956243 | 0.91 | MAOB (0.58) | MAOBCCR5USP2LMNAMAOA | |
| SCHEMBL13956250 | 0.91 | MAOB (0.58) | MAOBCCR5USP2LMNAMAOA | |
| SCHEMBL13956196 | 0.88 | MAOB (0.57) | MAOBCCR5MAOA | |
| SCHEMBL1878476 | 0.84 | HPGD (0.50) | MAOBLMNASMN1; SMN2 | |
| SCHEMBL13785972 | 0.84 | MAOB (0.62) | MAOBMAOA | |
| SCHEMBL4957945 | 0.82 | HPGD (0.52) | MAOBLMNASMN1; SMN2 | |
| SCHEMBL4957949 | 0.82 | HPGD (0.52) | MAOBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090099355-A1 | Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids | MICROBIA, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099355-A1 | Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids | MICROBIA, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099355-A1 | Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids | MICROBIA, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080287663-A1 | Process For Production Of 4-Biphenylyazetidin-2-Ones | MICROBIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287663-A1 | Process For Production Of 4-Biphenylyazetidin-2-Ones | MICROBIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287663-A1 | Process For Production Of 4-Biphenylyazetidin-2-Ones | MICROBIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080200669-A1 | Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones | MICROBIA, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200669-A1 | Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones | MICROBIA, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200669-A1 | Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones | MICROBIA, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287663-A1 | Process For Production Of 4-Biphenylyazetidin-2-Ones | CYP4Z1, CYP4F12, CYP4F2 | MAOB 312/4885CCR5 4508/4885USP2 2534/4885 |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | MAOB 722/4885CCR5 3409/4885USP2 1831/4885 |
| US-20080200669-A1 | Processes For Production of Phenolic 4-Biphenylylazetidin-2-Ones | CYP4B1, CYP4F2, CYP4F12 | MAOB 126/4885CCR5 4582/4885USP2 1755/4885 |
| US-20090099355-A1 | Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids | PIK3CA, PPA1, PIK3CB | MAOB 588/4885CCR5 4654/4885USP2 2424/4885 |
| US-20090186834-A1 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | NPC1L1, CYP46A1, NPC1 | MAOB 1740/4885CCR5 1774/4885USP2 2460/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | MAOB 457/4885CCR5 3977/4885USP2 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.